lunedì, 7 settembre 2026

Notizie AIOM – anno XVI n. 681

FDA Adds PD-L1 Expression to Frontline Pembrolizumab, Atezolizumab Urothelial Carcinoma Labels

June 20, 2018 - The FDA has incorporated PD-L1 status into the labels for pembrolizumab and atezolizumab for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma, based on lower overall survival (OS) rates with the PD-1/PD-L1 inhibitors ...
Leggi tutto

FDA and EMA Accept Regulatory Submissions for Review of Talazoparib for Patients With Germline BRCA-Mutated Metastatic Breast Cancer

June 15, 2018 - The U.S. Food and Drug Administration (FDA) recently accepted for filing and granted Priority Review designation a new drug application for talazoparib. The submission is based on results from the EMBRACA trial, which evaluated talazoparib vs chemotherapy ...
Leggi tutto

Interested in joining the Committee for Advanced Therapies (CAT) to represent patients’ associations or clinicians?

June 21, 2018 - The European Commission has published a call for expressions of interestExternal link icon for representatives of patients’ organisations and clinicians to join the European Medicines Agency’s (EMA) Committee for Advanced Therapies (CAT) as members ...
Leggi tutto

Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update

In 2016, ASCO published a guideline to assist in clinical decision making in metastatic pancreatic cancer for initial assessment after diagnosis, first- and second-line treatment options, palliative and supportive care, and follow-up. The purpose of this update is to incorporate ...
Leggi tutto

Dal Soroptimist International Club Genova a favore delle ragazze STEM

Il Premio, del valore di 2.000 Euro, sarà attribuito ad una Tesi di Laurea Magistrale in campo Emato-Oncologico, discussa da una studentessa dell’Università degli Studi di Genova negli anni accademici 2016-17 o 2017-18, in una delle seguenti discipline: ...
Leggi tutto

FDA Clears Expanded Indication of Scalp-Cooling System

June 18, 2018 - Paxman’s advanced scalp-cooling system has now been cleared by the US Food and Drug Administration (FDA) for use during treatment of patients with solid tumors. The system is now indicated to reduce the likelihood of chemotherapy-induced alopecia in ...
Leggi tutto

Statement from Douglas Throckmorton, M.D., deputy center director for regulatory programs in FDA’s Center for Drug Evaluation and Research, on the agency’s response to ongoing drug shortages for critical products

June 19, 2018 - Among the biggest challenges health care providers and patients face are shortages of medically necessary medications. These shortages greatly impact patient treatment options and require practitioners to make difficult decisions that can compromise care, ...
Leggi tutto

FDA Strategizes to Step Up Introduction of Lower-Cost Drugs and NGS

June 19, 2018 - The market for biosimilar introduction is “extremely unstable,” but the FDA is working to ease the launch of more affordable cancer medicines, both biosimilars and generics, with a strategy that includes an attempt to reduce anticompetitive behavior, ...
Leggi tutto

Prevalence of beliefs about actual and mythical causes of cancer and their association with socio-demographic and health-related characteristics: Findings from a cross-sectional survey in England

Literature on population awareness about actual causes of cancer is growing but comparatively little is known about the prevalence of people's belief concerning mythical causes of cancer. This study aimed to estimate the prevalence of these beliefs and their association ...
Leggi tutto

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO

Right-sided metastatic colorectal cancer (mCRC) patients have poor prognosis and achieve limited benefit from first-line doublets plus a targeted agent. In this unplanned analysis of the TRIBE study, we investigated the prognostic and predictive impact of primary tumor sidedness ...
Leggi tutto